What one share of Zevra Therapeutics holds
We are a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. We are focused on expanding patient access, progressing our pipeline toward key milestones, and delivering meaningful therapeutics.
Zevra Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.28 |
|---|---|
| Profit | $0.96 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | $0.55 |
| Cash and investments | $2.45 |
| Debt | $0.00 |
| Book value | $3.67 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | $0.00 | −$35.12 | $0.34 | −$29.42 | — | −$163.07 |
| 2014 | $0.00 | −$164.33 | $0.32 | −$98.90 | — | −$325.96 |
| 2015 | $0.00 | −$118.69 | $0.29 | −$44.30 | — | −$11.18 |
| 2016 | — | −$18.10 | $0.70 | −$33.34 | — | −$20.42 |
| 2017 | — | −$47.37 | $0.20 | −$36.34 | — | −$62.78 |
| 2018 | $0.00 | −$50.39 | $0.02 | −$48.39 | — | −$40.26 |
| 2019 | $6.93 | −$13.23 | $0.01 | −$12.82 | — | −$32.77 |
| 2020 | $3.34 | −$3.21 | $0.01 | −$0.50 | — | −$14.64 |
| 2021 | $0.96 | −$2.11 | $0.00 | $0.35 | — | $2.90 |
| 2022 | $0.29 | −$0.78 | $0.00 | −$0.55 | — | $2.17 |
| 2023 | $0.77 | −$1.30 | $0.01 | −$0.95 | — | $1.49 |
| 2024 | $0.51 | −$2.28 | $0.00 | −$1.51 | — | $0.74 |
| 2025 | $1.86 | $1.35 | $0.01 | −$0.04 | — | $2.72 |
Common questions about Zevra Therapeutics
How much does one share of Zevra Therapeutics earn?
Over the last 12 months, each share of Zevra Therapeutics earned $0.96 of profit on $2.28 of sales, keeping about 42¢ of every $1 (profit margin).
Does Zevra Therapeutics pay a dividend?
Zevra Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Zevra Therapeutics’s book value per share?
Zevra Therapeutics’s book value is $3.67 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Zevra Therapeutics have?
Each share of Zevra Therapeutics has $2.45 of cash and investments and $0.00 of debt, as of June 30, 2026.
What is Zevra Therapeutics’s free cash flow per share?
$0.55 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Zevra Therapeutics bought back shares?
Zevra Therapeutics’s share count rose about 38379% from 2013 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.